Piramal Pharma Ltd
PPLPHARMABSE 543635PharmaceuticalsMkt cap ₹26,327 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹2,270 Cr
YoY +17.4%QoQ -17.5%
Net profit · Q1 FY27
₹-69.39 Cr
YoY —QoQ —
Net margin · Q1 FY27
-3.1%
+1.2 pts vs Q1 FY26
Net profit · FY26
₹-326 Cr
YoY -457.7%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 2,270 | 2,752 | 2,140 | 2,044 | 1,934 | +17.4% |
| Other income | 89.41 | 46.06 | 43.24 | 65.60 | 58.40 | +53.1% |
| Total income | 2,359 | 2,798 | 2,183 | 2,109 | 1,992 | +18.4% |
| Profit before tax | 0.00 | 29.43 | 0.00 | 0.00 | 0.00 | — |
| Tax | 61.93 | 51.83 | 42.33 | 53.04 | 2.68 | +2210.8% |
| Net profit | -69.39 | -8.82 | -136 | -99.22 | -81.70 | — |
| Net margin | -3.1% | -0.3% | -6.4% | -4.8% | -4.2% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | YoY |
|---|---|---|---|---|---|
| Revenue | 8,869 | 9,151 | 8,171 | 7,082 | -3.1% |
| Other income | 213 | 135 | 175 | 225 | +58.2% |
| Total income | 9,082 | 9,286 | 8,347 | 7,307 | -2.2% |
| Profit before tax | 0.00 | 342 | 120 | -174 | -100.0% |
| Tax | 150 | 324 | 161 | 66.31 | -53.7% |
| Net profit | -326 | 91.13 | 17.82 | -186 | -457.7% |
| Net margin | -3.7% | 1.0% | 0.2% | -2.6% |
BIC's take
We haven't covered Piramal Pharma Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 5:41 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.